Press Releases

All Releases

Summary Toggle Arbutus Consolidates HBV Business Around Warminster, PA Site

Feb 08,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a site consolidation and organizational restructuring to better align its HBV...

Read more
Summary Toggle Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences

Jan 16,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced the closing of the issue and sale of 664,000 series A participating convertible...

Read more
Summary Toggle Arbutus Announces Presentations at HepDART 2017

Nov 27,2017

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART 2017 being held...

Read more
Summary Toggle Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

Nov 16,2017

PDF Version

VANCOUVER, B.C. and WARMINSTER, Pa. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc....

Read more
Summary Toggle Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)

Nov 13,2017

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals,...

Read more
Summary Toggle Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results

Nov 02,2017

PDF Version

Strategic Investment from Roivant Extends Cash Runway Combination Study for ARB-1467 Starting in 4Q17 Company to Host a Corporate Update Conference Call Today at 4:15 PM ET VANCOUVER, British Columbia and WARMINSTER, Pa. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...

Read more
Summary Toggle Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results

Oct 31,2017

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, November 2, 2017 at 1:15 PM...

Read more
Summary Toggle Arbutus Presents HBV Data at 2017 AASLD Liver Meeting

Oct 24,2017

PDF Version

Phase 2 ARB-1467 Combination Study Starting in 4Q17 Expected IND-filings in 2018 for Two New Oral Compounds VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic...

Read more
Summary Toggle Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients

Oct 18,2017

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Gritstone Oncology, a leader in personalized cancer immunotherapies,...

Read more
Summary Toggle Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences

Oct 16,2017

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Roivant Sciences Ltd. announced today the closing of the issue and sale of 500,000...

Read more